Feed / HTFL

Heartflow, Inc.

HTFL

Healthcare · 49.88 +9.7% today

Isolated · not yet confirmedMarket checked 11 Sept, 15:55 GMT-4

Market read

Heartflow, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 1 directly disclosed connection is confirming.

Company+9.7% todayVolume comparison unavailable
Market group0 of 1 activeAI Coronary Diagnostics · unavailable
Disclosed network0 of 1 confirmingNo filing-linked name is confirming now
What would change this read
  • Heartflow says commercialization of Plaque Analysis and higher revenue case volume are supporting growth.
  • Hiring and training additional production personnel is offsetting part of the productivity benefit as case volume rises.

Invalidation: The isolated read changes if HTFL's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Health Information Services

No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 1 directly disclosed connection is confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • Heartflow says commercialization of Plaque Analysis and higher revenue case volume are supporting growth.
  • Hiring and training additional production personnel is offsetting part of the productivity benefit as case volume rises.

Company research

Understand the business, not just the ticker

As of Sep 12, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods3
Price observations276
Usable filing statements87
Verified relationships1
Evidence supporting the case
  • Latest annual revenue changed +39.9% year over year.
  • Operating margin changed +12.3 percentage points in the latest annual period.
  • Net margin changed +10.3 percentage points in the latest annual period.
Evidence challenging the case

No qualifying adverse evidence was identified; that is not proof there is no downside.

Questions before a position
  • EV/sales is 8391% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 11, 2026

49.88
6m+139.9%12m+49.0%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2023-12-31$87.2M$-25.32
2024-12-31$125.8M+44.3%$-17.98+9.8%
2025-12-31$176.0M+39.9%$-3.17

What management says matters

Persistent and emerging business drivers

Product pipeline and R&Dmixed · 3 filings
The increase in research and development expenses was primarily attributable to an increase of $8.6 million in personnel and related expenses directly associated with an increase in headcount, $0.8 million in allocated overhead, $0.7 million in consulting and…
10-Q · Aug 13, 2026
Foreign exchangenegative · 1 filings
The decrease was primarily attributable to the remeasurement and recognition of the change in fair value related to our common stock warrant liability charge of $2.5 million, partially offset by a benefit on the remeasurement and recognition of the change in…
10-Q · Sep 19, 2025

Valuation discipline

Descriptive valuation snapshot

Price/sales 10.4× · EV/sales 10.2×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Fewer than 4 annual revenue periods; too little history to scaffold scenarios.

Price action

How the market is pricing the story

49.88+9.7% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for HTFL. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for HTFL. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind HTFL

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depended on by

TEMTempus AI, Inc.competitorFeb 24, 2026

In cardiology we may compete with companies such as HeartFlow Inc.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

HTFL is currently a Leader in the organic co-movement group AI Coronary Diagnostics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for HTFL; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.